Untitled

Abstract

According to the World Health Organization (WHO) [1], 47.5 million people worldwide were affected by major neurocognitive disorder, characterized by symptoms that impact cognitive function. More specifically, in Canada, in 2018, there were approximately 452,000 individuals over the age of 65 diagnosed with major neurocognitive disorder [2], while in 2020, 597,000 Canadians were living with cognitive impairments, and this number is expected to reach 955,900 people by 2030. Considering the aging population and significant medical advances that extend life expectancy, in Canada as in other part of the world, the number of people living with cognitive impairments is projected to increase in the coming decades [3].Major neurocognitive disorder is a chronic condition typically characterized by a decline in cognitive functions, changes in physical condition, as well as mood and behavioral alterations [4]. The DSM-5 diagnosis of Major Neurocognitive Disorder, which corresponds to dementia, requires substantial impairment to be present in